Endologix today announced a leadership transition. Matt Thompson will step down as president and chief executive officer (CEO) and take on a new role as executive vice president and chief medical officer. John Liddicoat has been appointed as the new president and CEO, effective immediately.
Richard Mott, chairman of the board stated: “We are thrilled to welcome Dr John Liddicoat as our new CEO. John’s extensive experience and proven leadership in the healthcare industry make him the ideal person to guide Endologix through its next chapter of growth and innovation. I also want to extend our sincere appreciation to Matt for his exceptional leadership and the significant advancements he has brought to Endologix during his tenure as CEO. We are pleased that Matt will remain an integral part of our team, enabling him to balance his professional commitments with a desire to spend more time in the UK.”
A press release details that Liddicoat brings over 30 years of global healthcare experience to his new role. He has served on the boards of several private medical technology companies and advised private equity firms. Notably, Liddicoat spent more than 16 years in executive roles at Medtronic, where he led strategic initiatives and oversaw global operations for critical divisions, including the cardiac rhythm and heart failure business. He has taken products from concept through product development to global commercial launch. John graduated medical school from the University of Chicago, completed a residency in general and cardiothoracic surgery at Johns Hopkins Hospital, and graduated business school from Boston University.
Liddicoat stated: “I’m excited to join Endologix as president and CEO and build upon the company’s strong foundation. I look forward to collaborating with the team, to expand our impact, and improve outcomes for patients suffering from vascular disease around the world by delivering life-changing vascular solutions.”
